Who makes Co-Amlessa®?

Co-Amlessa® is developed by KRKA.

What development phase is Co-Amlessa® in?

Co-Amlessa® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Co-Amlessa®

KRKA · FDA-approved active Small molecule Quality 3/100

Co-Amlessa® is a marketed drug by KRKA with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Co-Amlessa®
Sponsor	KRKA
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results